Latest & greatest articles for terazosin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on terazosin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on terazosin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for terazosin

1. Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin. (PubMed)

Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin. A multicenter, double-blind study compared the antihypertensive efficacy and safety of doxazosin and terazosin as once-daily therapy. Doxazosin, a potent antihypertensive agent, selectively inhibits alpha 1 adrenoceptors. Its pharmacokinetic profile, including gradual onset of action, long plasma elimination half-life and long duration of action, permits once-daily dosing. Terazosin, a structural (...) analog of prazosin, also inhibits alpha 1 adrenoceptors and is recommended as once or twice-daily therapy. Nineteen (73%) of 26 patients randomly assigned to receive doxazosin were therapeutic successes; 17 (65%) achieved normalized blood pressure (defined as blood pressure less than or equal to 90 mm Hg). The mean final daily dosage in patients classified as therapeutic successes was 2.4 mg. Eighteen (64%) of 28 terazosin-treated patients were considered therapeutic successes; 16 (57%) achieved

1987 The American journal of cardiology

2. WITHDRAWN: Terazosin for benign prostatic hyperplasia. (PubMed)

WITHDRAWN: Terazosin for benign prostatic hyperplasia. Lower urinary tract symptoms associated with benign prostatic obstruction (BPO) occur in up to 70% of men over the age of 60 years. To relieve these bothersome symptoms, treatment options include alpha-antagonists, also know as alpha-blockers.We conducted a systematic review to evaluate the effectiveness and adverse effects of the alpha-blocker, terazosin, for treatment of urinary symptoms associated with BPO.Trials were searched (...) in computerized general and specialized databases (MEDLINE, Cochrane Library), by checking bibliographies, and by contacting manufacturers and researchers.Studies were included if they (1) were randomized trials of at least 1 month duration, and (2) included men with symptomatic BPO and compared terazosin with placebo or active controls.Study, patient characteristics and outcomes data were extracted in duplicate onto standardized forms utilizing a prospectively developed protocol. The main outcome measure

2011 Cochrane

3. Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review

Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

4. Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin

Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin (ADIES) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00449683 Recruitment Status : Completed First Posted : March 20, 2007 Last Update Posted : August 25, 2016 Sponsor: Thomas Jefferson

2007 Clinical Trials

5. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. (PubMed)

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. Men with benign prostatic hyperplasia can be treated with alpha 1-adrenergic-antagonist drugs that relax prostatic smooth muscle or with drugs that inhibit 5 alpha-reductase and therefore reduce tissue androgen concentrations. However, the effects of the two types of drugs have not been compared.We compared the safety and efficacy (...) of placebo, terazosin (10 mg daily), finasteride (5 mg daily), and the combination of both drugs in 1229 men with benign prostatic hyperplasia. American Urological Association symptom scores and peak urinary-flow rates were determined at base line and periodically for one year.The mean changes from base line in the symptom scores in the placebo, finasteride, terazosin, and combination-therapy groups at one year were decreases of 2.6, 3.2, 6.1, and 6.2 points, respectively (P<0.001 for the comparisons

1996 NEJM

6. [Amlodipine combined with terazosin reduces postvoid residual and the risk of acute urinary retention]. (PubMed)

[Amlodipine combined with terazosin reduces postvoid residual and the risk of acute urinary retention]. This prospective randomized double-blinded clinical trial was designed to explore the effects of amlodipine and the combination of amlodipine with terazosin in improving postvoid residual (PVR) in patients with lower urinary tract symptoms (LUTS) and concomitant hypertension.We randomly divided 360 LUTS patients with concomitant hypertension into a 5 mg amlodipine group, a 2 mg terazosin (...) group and a 5 mg amlodipine plus 2 mg terazosin group, and measured PVR at the baseline and 4 weeks after the treatment.For male patients with LUTS associate with hypertension, all of amlodipine (APVR = 6.8) , terazosin (APVR = 7. 6), and combination group (APVR = 8.8) can significant reduced the PVR (P < . 0.1), but no significant difference was found among three groups.Amlodipine alone or combined with terazosin can improve the PVR of the LUTS patient effectively, but had no significant difference

2009 Zhonghua nan ke xue = National journal of andrology

7. [An open randomized comparative trial of efficacy and safety of selective alpha-adrenoblocker setegis (terazosin) in therapy of patients with chronic bacterial prostatitis]. (PubMed)

[An open randomized comparative trial of efficacy and safety of selective alpha-adrenoblocker setegis (terazosin) in therapy of patients with chronic bacterial prostatitis]. An open randomized comparative trial of setegis (terazosine) has shown good subjective and objective results in patients with chronic bacterial prostatitis. The drug is well tolerated and produces insignificant side effects. It is also demonstrated that combined therapy with alpha-adrenoblockers is more effective

2007 Urologii͡a (Moscow, Russia : 1999)

8. Economic modelling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia

Economic modelling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia Economic modelling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia Economic modelling to assess the costs of treatment with finasteride, terazosin, and transurethral (...) ) treatment with finasteride, terazosin, and transurethral resection of the prostate for men (TURP). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Hypothetical population of men aged 55-75 years with at least moderate symptoms of prostatism. Setting The practice setting was hospital. The economic study was carried out in the US. Dates to which data relate Effectiveness data were obtained between 1988-1994. Resource data were obtained between 1994-1995

1995 NHS Economic Evaluation Database.

9. The influence of food on the oral bioavailability of terazosin. (PubMed)

The influence of food on the oral bioavailability of terazosin. 1685091 1992 02 27 2018 11 13 0306-5251 32 6 1991 Dec British journal of clinical pharmacology Br J Clin Pharmacol The influence of food on the oral bioavailability of terazosin. 775-6 McNeil J J JJ Drummer O H OH Raymond K K Conway E L EL Louis W J WJ eng Clinical Trial Letter Randomized Controlled Trial Research Support, Non-U.S. Gov't England Br J Clin Pharmacol 7503323 0306-5251 0 Adrenergic alpha-Antagonists 8L5014XET7 (...) Terazosin XM03YJ541D Prazosin IM Administration, Oral Adrenergic alpha-Antagonists pharmacokinetics Adult Biological Availability Food Humans Middle Aged Prazosin analogs & derivatives pharmacokinetics 1991 12 1 1991 12 1 0 1 1991 12 1 0 0 ppublish 1685091 PMC1368564 Br J Clin Pract Suppl. 1987 Dec;54:9-14 2905162 Am J Med. 1986 May 23;80(5B):20-4 2872802 Clin Pharmacokinet. 1980 Nov-Dec;5(6):583-90 7438656 Prostate Suppl. 1990;3:75-84 1689172 Am J Cardiol. 1990 Mar 1;65(9):638-43 1968703 J Cardiovasc

1992 British journal of clinical pharmacology

10. Issues in designing a randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome: Comment on Wang et al. Randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/ (PubMed)

Issues in designing a randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome: Comment on Wang et al. Randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/ 27378099 2019 03 11 2019 03 11 1573-2584 49 3 2017 03 International urology and nephrology Int Urol Nephrol Issues in designing a randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome: Comment on Wang et al. Randomized (...) controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. Int Urol Nephrol. 2016;48:13-18. 457-458 10.1007/s11255-016-1356-2 Papeš Dino D Department of Surgery, Clinical Hospital Center Zagreb, Kišpatićeva 12, 10000, Zagreb, Croatia. dinopapes@gmail.com. Pasini Miram M Department of Surgery, Clinical Hospital Center Zagreb, Kišpatićeva 12, 10000, Zagreb, Croatia. Jerončić Ana A Department of Research in Biomedicine

2017 International urology and nephrology

11. Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting

Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting (TZ-CAS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03195673 Recruitment Status

2017 Clinical Trials

12. [Therapy of benign prostatic hyperplasia: terazosin or finasteride?]. (PubMed)

[Therapy of benign prostatic hyperplasia: terazosin or finasteride?]. 9381019 1997 11 14 2013 11 21 1661-8157 86 34 1997 Aug 20 Praxis Praxis (Bern 1994) [Therapy of benign prostatic hyperplasia: terazosin or finasteride?]. 1305-6 Trinkler F B FB Urologische Klinik, Universitätsspital, Zürich. ger Clinical Trial Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Therapie der benignen Prostatahyperplasie: Terazosin oder Finasterid? Switzerland Praxis (Bern 1994 (...) ) 101468093 1661-8157 0 Adrenergic alpha-Antagonists 0 Enzyme Inhibitors 57GNO57U7G Finasteride 8L5014XET7 Terazosin XM03YJ541D Prazosin IM Adrenergic alpha-Antagonists administration & dosage adverse effects Double-Blind Method Enzyme Inhibitors administration & dosage adverse effects Finasteride administration & dosage adverse effects Humans Male Prazosin administration & dosage adverse effects analogs & derivatives Prospective Studies Prostatic Hyperplasia drug therapy Urodynamics drug effects 1997 8

1997 Praxis

13. Re: Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms. (PubMed)

Re: Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms. 8583558 1996 03 19 2017 09 08 0022-5347 155 3 1996 Mar The Journal of urology J. Urol. Re: Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms. 1039 Frankel G G eng Comment Letter United States J Urol 0376374 0022-5347 0 Adrenergic alpha-Antagonists 8L5014XET7 Terazosin XM03YJ541D Prazosin AIM IM J Urol

1996 The Journal of urology

14. Terazosin

Terazosin Top results for terazosin - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for terazosin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

15. Intraoperative floppy iris syndrome associated with terazosin (PubMed)

Intraoperative floppy iris syndrome associated with terazosin 17699957 2007 11 02 2018 11 13 0301-4738 55 5 2007 Sep-Oct Indian journal of ophthalmology Indian J Ophthalmol Intraoperative floppy iris syndrome associated with terazosin. 395-6 Venkatesh Rengaraj R Veena Kannusamy K Gupta Santhosh S Ravindran Ravilla D RD eng Case Reports Letter India Indian J Ophthalmol 0405376 0301-4738 0 Adrenergic alpha-Antagonists 0 Platelet Aggregation Inhibitors 8L5014XET7 Terazosin XM03YJ541D Prazosin IM

Full Text available with Trip Pro

2007 Indian journal of ophthalmology

16. Hemodynamic and endocrinological effects of a new selective alpha 1-blocking agent, terazosin, in patients with essential hypertension. Results of long-term treatment. (PubMed)

Hemodynamic and endocrinological effects of a new selective alpha 1-blocking agent, terazosin, in patients with essential hypertension. Results of long-term treatment. Thirteen patients with essential hypertension were treated with an alpha 1-adrenoceptor antagonist, terazosin (1 to 4 mg/day) for 12 months. To assess the mechanism of its antihypertensive effect, the hemodynamic and endocrinological responses to terazosin were determined before, 3, and 12 months after the administration (...) of terazosin. Blood pressure significantly decreased within 2 weeks after the start of terazosin and its effect was sustained throughout the 12 month period. Pulse rate did not change except slight increase in the third month. The hemodynamic studies revealed that total peripheral resistance significantly decreased and cardiac output slightly increased, indicating that the antihypertensive effect of terazosin is mainly produced by its vasodilation. Blood volume and plasma volume did not change. Although

1990 American journal of hypertension

17. A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. (PubMed)

A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. To explore the efficacy of levofloxacin, terazosin, and their combination in patients with category III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).A total of 115 patients with category III CP/CPPS receiving 6-week therapy were randomly divided into the levofloxacin group (n = 38), terazosin group (n = 38 (...) ), and combination group (n = 39). The primary endpoint was the response rate (i.e., the change from baseline) in the total and domain scores of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI). Secondary endpoints were expressed as prostatic secretion-white blood cell (EPS-WBC) and International Index of Erectile Function-5 (IIEF-5).After 6 weeks, the response rate of NIH-CPSI scores was 45.1, 22.4, and 50.0 % in the levofloxacin group, terazosin group, and combination group

2015 International urology and nephrology

18. Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating

Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00237510 Recruitment Status : Completed First Posted : October 12, 2005 Last Update Posted : March 5, 2014 Sponsor: Thomas Jefferson University Information

2005 Clinical Trials

19. Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up

Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record (...) Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal

2007 Clinical Trials

20. Effect of Amlodipine Monotherapy or Combined With Terazosin on Lower Urinary Tract Symptoms and Hypertension

Effect of Amlodipine Monotherapy or Combined With Terazosin on Lower Urinary Tract Symptoms and Hypertension Effect of Amlodipine Monotherapy or Combined With Terazosin on Lower Urinary Tract Symptoms and Hypertension - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Effect of Amlodipine Monotherapy or Combined With Terazosin on Lower Urinary Tract Symptoms and Hypertension The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00693199 Recruitment Status : Completed First Posted : June 6, 2008 Last Update

2008 Clinical Trials